Pricing Log in Create free account
Saturday 17 October 2026 Export BIIB’s income statement to Excel — free account

Biogen Inc.

BIIB Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.

232.65 2.70 −1.15%
Market cap
$34.8B
P/E
41.0×
Fwd P/E
31.5×
Dividend yield
—
F-score
4/9
Altman Z
3.13
Beneish M
−2.67
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Biogen Inc. (BIIB) Price to free cash flow

Alert me on Price to free cash flow

As of 16 October 2026, Biogen Inc. (BIIB) trades at a price to free cash flow of 13.5×. Over the past ten years it has ranged from 0.0× (September 2015) to 37.8× (October 2023); the current reading is higher than 52% of that period. That is below the Drug Manufacturers General industry median of 16.5× and below the Healthcare sector median of 20.2×.

Price to free cash flow, daily

Embed this chart

Annual newest first

Period Price to free cash flow Change
FY2025 12.8× 44.27%
FY2024 8.9× (71.77%)
FY2023 31.3× 36.40%
FY2022 23.0× 116.05%
FY2021 10.6× (0.70%)
FY2020 10.7× 23.66%
FY2019 8.7× (25.52%)
FY2018 11.6× (57.63%)
FY2017 27.4× 66.29%
FY2016 16.5× (24.49%)

Quarterly newest first

Period Price to free cash flow Change
Jun 2026 12.6× 11.80%
Mar 2026 11.2× (11.99%)
Dec 2025 12.8× 40.65%
Sep 2025 9.1× (8.88%)
42 more quarters

Against its own ten years

Low 0.0× High 37.8×
Ten-year median 13.3×
Current reading's percentile 52

Price to free cash flow against peers

Company Price to free cash flow
SNY Sanofi compare 6.7×
BMY Bristol Myers Squibb Company compare 10.7×
GSK GSK PLC Sponsored ADR compare 13.0×
BIIB Biogen Inc. 13.5×
GILD Gilead Sciences, Inc. compare 15.0×
PFE Pfizer Inc. compare 16.5×
NVO Novo Nordisk A/S compare 22.6×
AMGN Amgen Inc. compare 24.0×
AZN AstraZeneca PLC compare 40.9×
Drug Manufacturers General industry median 16.5×
Healthcare sector median 20.2×
Market median 14.2×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on BIIB